AKTS vs ALMS: fair value comparison
Aktis Oncology, Inc. and Alumis Inc. · Updated 2026-10-19
AKTS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ALMS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AKTS currently ranks higher by quality score.
| AKTS | ALMS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $15.06 | $6.12 |
| 12-month range | $15.06–$30.89 | $4.51–$30.30 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #174 of 301 Healthcare | #175 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | — | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AKTS fair value analysis · ALMS fair value analysis